
Junction Bioscience uses AI-driven closed-loop experiments to design new therapeutic candidates faster than traditional lab workflows. The company combines an autonomous AI scientist with lab-in-the-loop automation and machine learning models to generate hypotheses, plan experiments, and analyze biological data. Its platform operates as a biotech R&D product for drug discovery, integrating automated experimentation, data capture, and model-driven optimization. Junction primarily serves research organizations and drug developers aiming to accelerate preclinical discovery.

Junction Bioscience uses AI-driven closed-loop experiments to design new therapeutic candidates faster than traditional lab workflows. The company combines an autonomous AI scientist with lab-in-the-loop automation and machine learning models to generate hypotheses, plan experiments, and analyze biological data. Its platform operates as a biotech R&D product for drug discovery, integrating automated experimentation, data capture, and model-driven optimization. Junction primarily serves research organizations and drug developers aiming to accelerate preclinical discovery.
Founded: 2024
Headquarters: San Francisco area
Product: Autonomous AI scientist platform for drug discovery
Lead investor: Y Combinator
Preclinical drug discovery / AI-driven biopharma R&D
2024
Biotechnology
500000
“Backed by Y Combinator”